- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Lupin and YL Biologics Receive Japanese Approval for Etanercept Biosimilar
Lupin and YL Biologics announced today that they have received approval to manufacture and sell YLB113, a biosimilar etanercept product, in Japan. The product will be Lupin’s first biosimilar to come to the Japanese market.
Lupin and YL Biologics announced today that they have received approval to manufacture and sell YLB113, a biosimilar etanercept product, in Japan. The product will be Lupin’s first biosimilar to come to the Japanese market.
Cyrus Karkaria, PhD, president of Lupin, said in a statement that “the successful filing and eventual approval of YLB113 is a major step in the fight against [autoimmune] diseases, and will allow access to an effective, affordable equivalent. After significant investment in our biotechnology [research and development] division over the years, this is the first biosimilar for regulated markets developed in-house at Lupin and the first etanercept biosimilar developed by an Indian pharmaceutical player. It is an important achievement for us that sets the tone for future biosimilar development.”
Lupin submitted its application for the etanercept biosimilar to Japanese authorities in 2018 for all indications of the reference product. The application included data from a global phase 3 clinical trial of the drug, in comparison with the reference Enbrel, conducted at 110 centers in 11 countries.
The study’s primary endpoint was equivalent improvement in rheumatoid arthritis, measured by American College of Rheumatology (ACR) criteria for 20% improvement (ACR20), at week 24. YL Biologics reported in February 2018 that the proportion of patients achieving ACR20 fell within a prespecified equivalence margin used by most advanced regulatory agencies in granting marketing authorizations. The safety and immunogenicity of YLB113 were also similar to those of the reference Enbrel.
In addition to Japan, Lupin is targeting other major regulatory territories with its biosimilar etanercept; the drug maker announced in May 2018 that it has submitted a marketing authorization application for the biosimilar to the European Medicines Agency. In 2018, Lupin said that it would submit the biosimilar for US regulatory approval in the third quarter of 2020.
Health Canada Approves First Omalizumab Biosimilar
December 16th 2024Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
